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ALZHEIMER’S DISEASE:  
A REVIEW OF EXERCISE AS A PROTECTIVE FUNCTION 
CAMERON EVAN SCHMUTZ 
ABSTRACT 
Alzheimer’s disease (AD) is the leading cause of dementia accounting for 
between 60-80% of all dementia related cases. It is the 6th leading cause of death in the 
US and is the only one in the top 10 leading causes of death without a prevention or cure. 
As the life-expectancy across the world continues to increase, the number of AD cases 
are expected to likewise increase dramatically. 
AD is a multifaceted disease. There is no one pathway or genetic predisposition 
that researches can pinpoint as causing disease in all cases. Approximately 5-10% of 
cases are caused by an inherited genetic mutation, while 90-95% of cases are sporadic 
with determined underlying mechanism. This makes treatment for disease extremely 
difficult. In recent years focus has been given to modifiable risk factors to lower risk for 
AD, including exercise, diet, cardiovascular health, education, and smoking.  
This study reviews the possible protective effects of exercise on the development 
of AD. Randomized control trials (RCTs), longitudinal studies, and meta-analyses and 
studies in AD mouse models are scrutinized to determine whether there is an association 
between exercise and lower risk of AD, and to potentially pinpoint the molecular 
mechanisms behind this protective effect. The majority of studies concur that exercise 
does lower risk of AD, but the mechanisms still need to be elucidated. Although more 
research is needed, the results so far have been promising.  
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INTRODUCTION 
Alzheimer’s disease (AD) is the leading cause of dementia accounting for 
between 60-80% of all dementia related cases and affecting more than an estimated 5.5 
million people in the United States. It is the 6th leading cause of death in the US and 
currently has no effective treatment or cure. (Alzheimer’s Association, n.d.).  With the 
US population increasing in age the incidence of AD is expected to increase dramatically 
by the year 2050, with close to 16 million people in the US presenting with the disease. It 
has been estimated that between 2013 and 2050, persons over the age of 60 years old will 
more than double and that people over the age of 80 is expected to more than triple 
(Taurmi & Zhang, 2017).  In 2017, AD and other dementias are estimated to cost the US 
$259 billion and these costs are projected to only increase, rising to a staggering $1.1 
trillion by mid-century (Alzheimer’s Association, n.d.). This not only presents as a 
national health care crisis but also as a national financial crisis. 
Considering both the health and cost implications, it is imperative that a cure or 
effective preventative measure is found for this deleterious disease. Symptoms do not 
appear until years after initial physiological changes in the brain occur (Alzheimer’s 
Association). Additionally, a definitive diagnosis of AD cannot be determined until an 
autopsy is performed, which will reveal a preponderance of amyloid plaques and 
neurofibrillary tangles and reduced volume in the cortex and hippocampus (see Figure 1). 
Here we review the literature to evaluate the validity of the proposed positive impact of 
exercise on Alzheimer’s Disease. 
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Figure 1. Healthy brain vs Alzheimer’s Diseased brain.  (Left) View of a normal 
brain. Cortex and Hippocampus are healthy. (Right) View of a brain with Alzheimer’s 
disease. Cortex and Hippocampus are both shriveled, hallmarks of AD. (Figure from 
brainfacts.org). 
  
Symptoms 
         Symptoms of AD do not appear until years after initial molecular and 
physiological changes in the brain occur, adding to the difficulty of treating the disease. 
The earliest and most common symptom of AD is a progressive worsening ability to 
remember and recall new information. The gradual worsening of memory is thought to 
occur from the destruction of neurons by the buildup of Aβ plaques and neurofibrillary 
tangles in the hippocampus--the portion of the brain responsible for forming new 
memories--as well as neuronal inflammation. Other early symptoms include 
neurobehavioral symptoms like sleeplessness, delusion, agitation, apathy, depression, 
impaired communication, confusion, and behavior changes (Alzheimer’s Association). 
         As the disease progresses, it causes the affected individual to lose the ability to 
perform daily activities on his/her own. The disease gradually deprives a person from 
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being able to bath, dress, walk, and eventually swallow. Alzheimer’s disease progression 
varies from individual to individual with most people living between 4 and 8 years from 
initial diagnosis, while others living up to 20. Persons with advanced stages of AD 
require 24-hour assistance. This around the clock care is physically, emotionally, and 
financially taxing on caregivers and loved ones. 
Adding to the difficulty of treatment, symptoms alone are not enough to diagnose 
AD. An autopsy is required to give a definitive diagnosis, which will reveal Aβ plaques 
and neurofibrillary tangles, along with a reduced volume in the cortex and hippocampus 
(Alzheimer’s Association). 
 
Molecular Mechanisms of AD Pathology 
         Alzheimer’s disease pathology is characterized by the accumulation of 
inflammation, Aβ plaques, and neurofibrillary tangles in the brain. Most experts agree 
that AD development is a multifaceted mechanism and cannot be attributed to a single 
cause. The most common and perhaps most accepted theory in the development of AD is 
the “amyloid cascade” hypothesis, which asserts that the disease is triggered by an 
accumulation of Aβ plaques which form in the brain from the improper cleavage of the 
APP protein. These toxic plaques then initiate several downstream mechanisms that cause 
neurofibrillary tangles from the aggregation of Tau protein inside neurons and an 
increasingly toxic level of neuroinflammation (Ebrahimi et al., 2017 & Correia et al., 
2011, Alzheimer’s Association). 
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I would add here a paragraph and figure about APP processing, so it is easy to follow the 
rest of the thesis. 
 
Genetics of Alzheimer’s Disease 
         There are two broad categories of AD, Familial (FAD) or Early Onset and 
Sporadic or Late Onset (LOAD). FAD represents roughly 5-10% of all AD patients and 
is characterized by the presence of AD like symptoms before 65 years old, with 
symptoms showing as early as 30 years of age. FAD is caused by a genetic mutation in 
the APP, PSEN1, or PSEN2 genes (Ebrahimi et al., 2017). These genes directly cause 
disease and are considered deterministic. A mutation present in APP or PSEN1 results is 
100% of people developing AD, while a mutation in PSEN2 is results in approximately 
95% of people developing disease (Alzheimer’s Association). 
Interestingly, since APP is located on chromosome 21, approximately 50% of 
individuals with Down Syndrome develop AD in their lifetimes. It is hypothesized that 
the 3rd copy of the 21st chromosome causes an overabundance or production of APP and 
thus an overproduction of Aβ oligomers and plaques (Alzheimer’s Association).   
         The majority of AD cases are LOAD, accounting for roughly 90-95% of all cases. 
There are approximately 20 genes that have been implicated in increasing a person’s risk 
for developing disease, the most prevalent being the APOE E4 allele. APOE has 3 alleles: 
E2, E3, and E4. Inheriting the E4 allele dramatically increases an individual's risk for AD 
while inheriting the E2 allele decreases risk for AD. Although, the main function of 
APOE is transporting cholesterol, is also regulates Aβ metabolism (Kanekiyo et al., 
 5 
2014). It also exists in AB plaques and can affect the formation and clearance of 
extracellular Aβ (Honjo et al., 2012 and Strittmatter et al., 1993). 
Several other genes have been implicated in increasing risk for disease including: 
PICALM, CLU, CR1, BIN1, MS4A, CD2AP, EPHA1, ABCA7, SORL1, TREM2, 
PLD3, HLA-DRB5/HLA0DRB1, PTK2B, SLC24A4-0RING3, DSG2, INPP5D, MEF2C, 
NME8, ZCWPW1, CELF1, FERMT2, and CASS4 with more being discovered (NIH 
study, 2013, Karch et al., 2014). Although not deterministic, mutations in these genes do 
significantly raise the risk of developing AD during a person’s lifetime. 
 
Risk Factors 
         In addition to family history--especially when having a first-degree relative with 
AD--and the inheritance of the APOE-e4 allele there are other risk factors for disease, 
including age (Green et al., 2002). Indeed, the single greatest risk factor for developing 
AD is age. Estimates have shown that 3% of people between the ages of 65-74 have AD, 
17% of people between the ages of 75-84 have AD, and 32 to 50% of people over 85 
show symptoms of disease (Prince et al., 2013). With the average life expectancy across 
the globe increasing each year, the number of AD cases are expected to rise dramatically 
by mid-century and with it, the health care costs for patients suffering with AD.   
 
Modifiable Risk Factors 
         While age, family history, and genetics cannot be altered, we can potentially 
modify and control several other risk factors for developing AD. These include, but are 
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not limited to, education level, exercise, social and cognitive engagement, traumatic brain 
injuries, cardiovascular health, and depression. 
 A 2014 population-based analysis by Norton et al., suggests that possibly up to a 
third of all AD cases can be attributed to modifiable risk factors. The risk factors they 
identified are diabetes mellitus, midlife hypertension, midlife obesity, physical inactivity, 
depression, smoking, and low educational status. Researches estimated that a 10% 
reduction in the prevalence of risk factors per decade, by the year 2050, could reduce the 
number of AD cases by 8.7% in the US alone. And a 20% reduction could reduce the 
prevalence of AD by up to 16.3% in the US. This is a huge population in the US--
between 0.8 and 1.5 million people--that could possibly avoid the devastation of AD (see 
Figure 2). They also found that the largest proportion of AD cases in the US could be 
attributed to physical inactivity.  
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Figure 2. Projected AD Prevention Percentages. Projected percentages of AD cases 
that could be prevented, with 10% or 20% reduction per decade in the relative prevalence 
of the seven risk factors. (From Norton et al., 2014) 
  
Therefore, as scientists come closer to developing drugs to treat disease, many 
scientists are now also studying the possible protective effects of modifiable risk factors. 
Several recent studies have linked physical activity and AD. Mounting evidence suggests 
that aerobic exercise could be a viable option in delaying onset of AD and/or alleviating 
symptoms of disease. The purpose of this review is to examine the impact of exercise on 
cognition and AD at the epidemiological and molecular level.  
 
CURRENT LITERATURE REVIEW 
Several studies have been published in the last 10 years to determine the benefits 
exercise has on persons with AD with varying results. The discrepancy in results can be 
 8 
attributed to the high heterogeneity within and across studies, including exercise type, 
neuropsychological tests, severity of AD, age, sex, and race. Most agree that exercise 
offers some improvements in living standards and some forms of cognition (executive 
function, global cognition, verbal frequency), but to what extent is debated. Additionally, 
the molecular mechanisms of how exercise provides the cognitive benefits is still 
unknown. Here we review several of the prevailing hypotheses. 
 
Epidemiological Studies 
          
Randomized Control Trials (RCT) 
In 2014, Ohman et al. conducted a systematic review of 22 RCTs from 1991 to 
2013 that included 1,699 participants: 1,021 subjects with Mild Cognitive Impairment 
(MCI) and 678 with dementia (See Table 1). The researchers found that most of the 
studies done were of poor methodological quality and caution that the results be 
interpreted with that in mind.  The studies also had high levels of heterogeneity between 
them. 
Nevertheless, Ohman et al. concluded that physical exercise had the most 
cognitive benefit in persons with MCI. These benefits were mainly seen on global 
cognition, executive function, and attention. They found that the results on persons with 
dementia were inconclusive and more research needs to be done with high 
methodological quality. In this regard, Ohman et al. suggests having larger sample sizing, 
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longer exercise programs, better and longer follow up, and more rigorously defined levels 
of dementia. 
 
Table 1. Results from 22 RCTs between 1991-2013. Table measures various types of 
cognition and memory. (From Ohman et al, 2014) 
 
In a 2011 systematic review, Littbrand et al. came to several of similar 
conclusions as Ohman et al. They identified 10 RCTs that studied the cognitive and 
physical benefits of walking and exercise in persons with AD and living in residential 
care facilities. However, even though Littbrand et al. concluded that there may be some 
physical functionality benefit, they could not come to any conclusions on positive 
cognitive effects due to poor methodological quality of the studies reviewed. They concur 
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with Ohman et al. by suggesting new RCTs of higher scientific quality are needed to 
elucidate any protective or positive cognitive effects of exercise on AD patients. 
In another 2014 systematic review and meta-analysis of 6 RCTs, Farina et al. 
found that there was a possible positive effect on rate of cognitive decline between people 
with AD and physical exercise. Researchers focused their review on 6 RCT studies (these 
same studies were among the 22 RCTs in Ohman et al., 2014) that had clear exercise 
programs, cognitive tests, and only evaluated AD subjects. Although they found evidence 
for a positive correlation between cognitive decline and exercise, they cautioned that 
methodological heterogeneity limits their conclusions. They stated that due to the 
heterogeneity of exercise regimens throughout the 6 studies, it is impossible to determine 
the optimal type and intensity for cognitive improvement. 
Several RCTs have been conducted in the years since the systematic reviews by 
Ohman et al., Littbrand et al., and Farina et al., most of which have shown a positive 
protective effect aerobic exercise on neuropsychiatric signs and symptoms, as well as on 
physical strength and the ability to perform activities of daily living (ADLs). Two studies 
done by Telenius et al. and Fleiner et al. showed significant reductions in 
neuropsychiatric signs like depression, apathy, and agitation through aerobic exercise. 
Neither studies considered cognition or performed any cognitive tests. The studies 
focused instead on effect exercise has on ADLs and neuropsychiatric improvements. 
Both studies showed improvement in these two categories with aerobic exercise. The 
authors of each study suggested more robust sample sizes in further studies. 
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A 2015 study by Yang SY et al. showed that aerobic exercise was protective 
against AD. The study brought together 50 volunteers with cognitive impairment between 
the ages of 50 and 80 years old. The subjects were randomly split evenly into a control 
group and an exercise group, which consisted of 40-minute exercises 3 times a week for 3 
months. Yang SY et al. concluded aerobic exercise can improve cognitive function in 
persons with mild AD. 
Ohman et al. (2016) performed a RCT that divided participants into two cohorts: a 
home-based exercise cohort and group-based exercise cohort. Each group exercised twice 
a week for 1 year and were compared with a control group. They found that after 12 
months there was significant executive function improvement in the home-based cohort 
in comparison with the control group, although the same results were not found between 
the group-based cohort and the control group. They also found that all groups declined in 
verbal fluency and in the Mini-Mental State Examination. Ohman et al. concluded that 
exercise may be slightly beneficial for executive function, but positive correlations were 
not found for semantic memory or global cognition. Although, enhancements in ADLs 
were shown. 
A study by Yu et al. (2017) corroborates the findings by Ohman et al., also 
concluding that aerobic exercise may help maintain executive function in persons with 
dementia. Researchers conducted a 6-month trial of aerobic exercise on community-
dwelling adults with mild to moderate AD. They determined that aerobic exercise may 
offer a positive effect on executive function in individuals with AD but suggest future 
RCTs be conducted to support their conclusions. 
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 A previous pilot study by Yu et al. (2013) also followed a group of AD patients in 
community-dwelling for 6 months, during which they did an exercise program. They 
concluded that aerobic exercise may have beneficial results on executive function as well 
as depression but saw a downward trend in global cognition. They recommended future, 
robust RCTs.  
Toots et al. primarily looked to measure changes in global cognitive function and 
executive function in persons with AD. Participants exercised based on the High-
Intensity Functional Exercise (which is mostly non-aerobic) for 45 minutes, 5 times per 
2-week period over 4 months. Toots et al. used the Mini-Mental State Examination and 
Alzheimer’s Disease Assessment Scale-Cognitive Subscale to assess global cognition. 
Researchers concluded that the High-Intensity Functional Exercise had no positive effects 
on global cognition or executive function. They did find, as in previous studies, an 
increased ability to perform ADLs. 
In a separate study by Portugal et al. in 2016, researchers focused on strength 
training exercises, as opposed to aerobic exercise, and its effect on AD. To investigate 
this, they performed a somewhat comprehensive review of research done on strength 
training and AD. They found that strength training has an unclear effect on cortical 
atrophy and cerebral blood flow and a positive effect on the neurotransmitters IGF-1 and 
BDNF. They concluded that strength training may be useful in neurogenesis and 
neuroplasticity. 
Hoffmann et al. evaluated approximately 200 persons with mild AD that 
participated in an aerobic exercise regimen. The research did not find a significant 
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correlation of exercising and increased cognition. Rather, they discovered a connection 
with improved neuropsychiatric symptoms that accompany AD, including depression, 
dysphoria, apathy, irritability, etc. 
A 2017 study by Morris et al. found similar results in functional ability and 
ADLs. They also measured memory, executive function, and depression. They had 76 
probable AD patients who participated in 150 minutes of aerobic exercise per week for 
26 weeks. Along with improved ADLs, Morris et al. found indirect evidence that 
improved cardiorespiratory fitness was positively associated with memory performance 
and bilateral hippocampal volume. Aerobic exercise did not attenuate cognitive AD 
symptoms, this only occurred when those exercises were met with improved 
cardiorespiratory fitness. 
In summary the RCTs evaluated here provide an inconclusive analyses of the 
effects aerobic exercise have on the progression and development of AD. Several studies 
show a possible positive correlation in executive function, neuropsychiatric symptoms, 
and ADLs but only one of them found a positive correlation in global cognition. There 
are several possible reasons for these results including varying intensities of exercise, 
different types of exercise, and poor methodological quality. But perhaps, a prevailing 
reason could be that AD symptoms were already present when the therapy of exercise 
was administered. Although evidence suggests exercise to be beneficial in living 
standards for persons with AD, it seems it can’t reverse or slow the major cognitive 
deficits of disease. It may be necessary for exercise to be administered before onset of 
symptoms to have a protective role in cognitive function.  
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         Meta Analyses 
Several meta analyses have been performed assessing the protective role of 
exercise on cognition in AD patients. Most of them agree that there is a positive 
correlation between the two. As discussed previously, additional studies need to be done 
to corroborate these findings. 
The earliest analysis we will discuss here is a 2009 study from Hamer & Chida. They 
included 16 prospective studies in their analysis with a total of 163,797 non-demented 
participants at baseline and with 2,731 AD/dementia cases at follow up. Researchers used 
random effects modelling to allow for heterogeneity between studies. Their results 
suggest that physical activity reduces the risk for AD by up to 45%. Although, they 
determined that it is unclear at what time in a person’s life exercise is most important for 
protection against AD, and they were not able to determine an optimal dose of physical 
activity. Hamer & Chida offered several theories on the mechanisms of how exercise 
provides its protective effects but did not expound on any of them. 
A meta-analysis on RCTs by Groot et al. found that aerobic—not non-aerobic—
exercise had positive cognitive results and increased benefit on ADLs in AD patients. 
Three exercise groups were created: an aerobic group, non-aerobic group, and a group 
that did both. Researchers also concluded that both high frequency and low frequency 
exercise interventions promote positive cognitive effects in AD patients. They also 
suggested that exercise interventions of more than 150 minutes per week did not provide 
any additional protection or positive effects. 
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Similarly, a meta-analysis on RCTs by Cai et al. found a positive effect of 
exercise intervention on cognitive function in AD patients. They concluded that even low 
to mid-frequency exercise had positive effects, similar to what was concluded by Groot et 
al. 
In comparison, a 2017 study by Guure et al. found a strong association between 
high physical activity and cognitive maintenance in AD subjects. Researchers employed 
the Bayesian parametric and nonparametric approaches to control for bias and 
heterogeneity. They found that high intensity physical activity reduces risk by 38% and 
moderate exercise by 29%. 
In contrast to each of the above meta-analyses, Forbes et al. found no evidence 
that physical activity improves cognition in persons with dementia. They did not 
distinguish between types of dementia. They reviewed 17 trials with 1,067 participants. 
Researchers also did not find any evidence that exercise was beneficial for 
neuropsychiatric symptoms including depression, although they did find benefit for 
ADLs. Forbes et al. acknowledges the study had high heterogeneity and cautions the 
interpretation of results. 
 
Twin Study 
A 2008 study by Andel et al. evaluated the role of exercise at midlife and AD in 
human subjects. This was done by comparing the midlife physical activity of 90 sets of 
twins, with one twin in each pair experiencing dementia. The level of activity was self-
reported in many instances, which proves to be problematic, given that some patients had 
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dementia. Despite this, when controlled for age, sex, education, smoking, alcohol 
consumption, diet, BMI and angina, the study concluded that even light exercise in 
midlife can decrease a person’s risk for AD. 
Overall, these meta-analyses and twin study conclude that physical exercise 
lowers the risk of developing AD and aids in maintaining of cognitive function in AD 
patients. However, in the analysis by Forbes et al. that didn’t find this correlation, it was 
acknowledged several times throughout the study that the high heterogeneity could skew 
results. Despite this one study the majority of studies suggest that exercise can potentially 
be a powerful risk reducer in the development of AD. Even when assessing RCTs they 
found a positive association between exercise and cognitive maintenance. This is 
compelling evidence that a healthy, exercise filled lifestyle can act as a deterrent for 
disease. A reasonable future step should be evaluating the right dosage of exercise and 
time of application that will lead to the greatest results. 
 
Preclinical Studies 
Evidence from epidemiological studies suggest that exercise can lower the risk of 
developing AD and possibly help maintain cognition in persons who are already 
demented, but the molecular mechanisms still need to be elucidated. It is evident that 
exercise induces some changes in APP processing to lower the Aβ load, but it is difficult 
to know exactly how. Preclinical studies in mice also link exercise with AD 
development/progression and have identified potential genes involved in the response to 
exercise. 
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Several studies have also concluded that exercise improves Aβ load, tau 
phosphorylation, and neuroinflammation although not offering a mechanism or even 
addressing the regulation of genes. For example, Tapia-Rojas et al. conducted aerobic 
exercise experiments over 10 weeks with double transgenic APP mouse models. They 
found that volunteer running (mice are not shocked or otherwise coerced to run) 
decreased Aβ load and tau phosphorylation, neuroinflammation, and prevented cell loss 
in the hippocampus, increased neurogenesis in the dentate gyrus, and improved cognitive 
performance in their AD mouse models. Researchers did not determine if the running has 
its effect on APP process or Aβ clearance or both, and researchers did not determine the 
molecular mechanisms behind their findings. 
Zhang et al. studied APP/PS1 transgenic AD mouse models and found that 
aerobic exercise maintains white matter volume and capillaries in white matter. They also 
found that aerobic exercise improved spatial learning and memory in AD mice.  
In a systematic review in 2016, Ryan et al. investigated the possible benefits of 
exercise on neuroinflammation, cognition, and neurogenesis in mouse models of AD. 
They provide evidence from previous research that neurogenesis in the hippocampus is 
imperative to adult memory and cognition, and that neuroinflammation reduces 
neurogenesis in the hippocampus and directly contributes to the development of AD. In a 
comprehensive study and analysis of previous research done in mouse models, Ryan et 
al. concludes that aerobic exercise decreases amyloid pathology, increases neurogenesis 
in the hippocampus, and has potent pro-neurogenic and pro-cognitive effects. 
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APP Processing and BACE 1 
Several studies have pointed to a decrease in Beta Secretase 1 (BACE1)—which 
is a transmembrane protease that catalyzes the first step in the formation of amyloid beta 
peptide from APP—as the main factor in the decrease of Aβ, but MacPherson et al, 2017 
argues that exercise results in improvements in total adiposity, circulating metabolites, 
glucose intolerance, and insulin sensitivity which makes it difficult to determine what 
exactly affects APP processing (PubMed. 
BACE1 is the rate-limiting step in the production of β-amyloid and can be 
considered a biomarker for early AD detection. Therefore, it should also be looked at as a 
potential therapeutic target. In an AD brain, there are no changes in BACE1 mRNA, 
however BACE1 enzymatic activity is upregulated. Interestingly, in aerobic exercise 
studies, it has been shown that BACE1 expression levels and activity are downregulated 
in the brain. Studies have also shown that when administered BACE1 inhibitors, rat 
models do not develop β-amyloid plaques. 
MacPherson asserts that modifiable risk factors like inactivity, obesity, and 
insulin resistance may be partly to blame for the increase in BACE1 activity. MacPherson 
found that a single bout of exercise decreases BACE1 activity by inducing BDNF to exert 
a positive downstream effect on α -secretase and inducing TrkB to exert a prohibitive 
downstream effect on BACE1, thereby decreasing total Aβ load (See Figure 3).  
However, the exact mechanism remains unknown.  
 19 
  
Figure 3. Hypothesized Mechanism of Exercise Aβ Prevention Hypothesized 
mechanism that exercise has on preventing Aβ build up. (From MacPherson et al, 2017)  
 
Similarly, Kang et al. found that aerobic (treadmill) exercise prevented memory 
impairment from PSEN2 in a mouse model and reduced Aβ deposition through the 
inhibition of BACE1 activity or levels of expression. They showed that PSEN2 mice who 
exercised had lower Aβ deposition and less cognitive impairment, as well as lower levels 
of BACE1 and its product, C-99, in the hippocampus. Results also showed 
downregulation in several other genes included in inflammation and apoptosis. They 
concluded that aerobic exercise is protective against AD because it downregulates 
 20 
BACE1 expression, ER stress, and inflammation, and not only inhibits Aβ production but 
removes existing Aβ plaques.  
Cho et al. drew the same conclusions as the above-mentioned studies. They also 
found that BACE1 expression and its end-product were significantly reduced with 
aerobic (treadmill) exercise in a triple transgenic AD mouse model when compared to the 
same mouse model without exercise. They also showed reversal of memory loss and AD-
like symptoms, lower Aβ and hyper-phosphorylated tau, and increased in BDNF. Dao et 
al. found that running protects BDNF, calmodulin, and calcineurin expression, as well as 
prevents impairment in the dentate gyrus and signaling pathways. 
In a separate systematic review by Ebrahimi et al., researchers proposed that 
physical exercise exerts its effects by lowering APP, PSEN1, Aβ load, and BACE1, 
which is part of a duo of enzymes, including γ-secretase, that cleaves APP to generate 
Aβ, and by increasing neprilysin (NEP) and insulin degrading enzyme (IDE), which work 
together to determine and lower Aβ concentration (See Figure 4). The authors do not 
suggest a mechanism for how these genes are upregulated. 
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Figure 4. Results of Exercise on APP, BACE1, etc. Figure showing the results of 
physical activity on APP, BACE1, PSEN1, Aβ, NEP, and IDE and their subsequent 
influence on risk of developing AD. (From Ebrahimi et al. 2017.) 
 
The same review highlights recent evidence that exercise may inhibit the 
deleterious memory deficits caused by PS2 mutations, may inhibit activation of β-
secretase, and may reduce Aβ42 deposition in the hippocampus (Ebrahimi et al., 2017). 
Physical activity has also recently been shown to be especially helpful in persons who 
have the APOE ε4 allele. Several studies suggest that physical exercise is just as effective 
or more in persons with APOE ε4 than non-carriers (Ebrahimi et al., 2017). 
In contrast, Adlard et al. did not find a relationship between physical activity and 
a change in levels of BACE1, NEP, or IDE. Although, researchers did show a decrease in 
the overall Aβ burden. 
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Overall, AD mouse models seem to almost collectively agree that aerobic 
(treadmill) running offers protective effects in the development of AD (See Figure 5). 
Despite the remaining questions on the exact molecular mechanisms induced by aerobic 
exercise, several of the above studies agree that exercise causes a reduction in Aβ load, 
tau pathology is ameliorated, neuroinflammation is decreased, BDNF is increased, 
neurogenesis is increased especially in the dentate gyrus, and so is cognitive 
performance. 
 
 
 
Figure 5. Molecular Changes in AD Mouse Model. Compares the molecular changes 
that occur in the brain of a Sedentary AD Mouse and Active AD Mouse. (From Ryan et 
al. 2016) 
 
 
 23 
BDNF & Ketones  
In recent years, Brain Derived Neurotrophic Factor (BDNF) has received 
attention for its possible protective role in AD pathology. BDNF aids in and enhances 
neurogenesis (both in proliferation and on survival), synapse formation, learning & 
memory, and neuronal stress resistance (Nigam et al., 2017, BDNF, Binder and 
Scharfman, 2004). Additionally, it has been observed that BDNF protein is rapidly and 
significantly increased in the hippocampus during contextual learning, and that blocking 
BDNF impairs spatial learning (Binder and Sharfman, 2004). Other studies have also 
demonstrated an upregulation of BDNF in dorsal root ganglion cells as well as 
hippocampal and cortical neurons during exercise (Huang and Reichardt, 2001). 
Reduction in BDNF mRNA in the hippocampus has been shown in Alzheimer’s disease 
specimens (Ferrer et al., 1999; Phillips et al., 1991, Murer et al., 2001).  
Research shows that BDNF increases with exercise throughout the brain and 
especially in the dentate gyrus, but the exact mechanism remains elusive (Dao et al., 
2015).  In a recent study Sleiman et al. discovered β-hydroxybutyrate --a ketone body 
created in the liver-- which upregulates BDNF expression in the brain. They proposed 
that D-β-hydroxybutyrate is induced by exercise and accumulates in the hippocampus 
where it acts as an inhibitor of class I histone deacetylases (HDACs) to specifically 
induce BDNF expression. HDACs are a class of enzymes that remove acetyl groups from 
an ε-N-acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA 
more tightly. In a 4-week trial of voluntary exercise, the BDNF promoter I and II 
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expression in the hippocampus increased significantly in AD and non-AD mice, as well 
as mature BDNF protein levels.   
 Recent evidence suggests that increased BDNF levels lead to less Aβ and Aβ 
Plaques and may have a direct effect on APP processing and Aβ build up through the 
upregulation of α-secretase. APP is cleaved by three enzymes: α, β, and γ secretase. β and 
γ secretase increase levels of Aβ 40 and 42, which results in the amyloidogenic pathway 
of AD (Heneka et al., 2015). In contrast α secretase cleaves APP and prevents Aβ 
generation and leads to the non-amyloidogenic pathways (Nigam et al., 2017) (See Figure 
6).  
 
Figure 6. Amyloid precursor protein and neural development. (From Nicholas and 
Hassan 2014) 
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Nigam et al. and MacPherson determined that BDNF increases α-secretase and 
lowers soluble Aβ in the hippocampus of transgenic AD mice. They hypothesized that 
exercise can shift the processing of APP to the non-amyloidogenic pathway by increasing 
BDNF levels, which will increase α-secretase. 
Although BDNF acts on Aβ, it has no known effect on tau proteins. Jiao et al. 
studied the relationship between BDNF and the hyperphosphorylation of tau detected in 
AD and found none. It has been shown that aerobic exercise does protect against tau 
pathogenesis, but this could be due to several factors (Gratuze et al., 2017). They did 
however find that BDNF protected against tau-related neurodegeneration. Interestingly, 
their research led them to discover that BDNF can alleviate behavior deficits and prevent 
neuronal loss, synaptic degeneration, and neurogenesis impairment without affecting tau 
hyperphosphorylation. 
While research into BDNF has uncovered possible therapeutic targets, there is 
still much to be done in terms of research and testing. Increases in BDNF in vivo have 
not shown strong enough evidence to reverse disease, most probably because it has never 
been administered at early stages. More research should be done on this topic. 
 
Neuroinflammation 
The “amyloid cascade” hypothesis has long been considered the most accepted 
theory in AD pathology. Neuroinflammation was thought to be a “late-stage event” in 
AD, with the activation of innate immune system through glial cells and proinflammatory 
markers responding to the buildup of Aβ (Balducci and Forloni, 2018, Heneka et al., 
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2015). The studies suggest that the neuroinflammation is often in response to the AB 
buildup (Balducci and Forloni, 2018). 
Increasingly more evidence shows that innate immune system activation actively 
contributes to AD pathogenesis, rather than arising as a bystander reaction to amyloid 
build up (Sarius and Heneka, 2017, Heneka et al., 2015). For example, a recent study by 
Sarius and Heneka, 2017 even found that inflammation and microglial activation occur 
before the onset of AD and may be a driving force in AD pathology. Although this 
finding needs to be further researched, it adds to the compelling narrative of the intimate 
relationship between neuroinflammation and the development or forwarding of AD.  
With an ever-growing body of research showing the relationship between AD and 
neuroinflammation, it becomes apparent that exercise may be valuable in the attenuation 
of AD symptoms through its anti-inflammatory effects. 
 
AD studies: exercise and inflammatory gene expression  
AD mice models and patients show an upregulation of several inflammatory 
genes including: HLA-DRB5/DRB1, INPP5D, MEF2C, CR1, TREM2, Tumor Necrosis 
Factor Alpha (TNF-α), IL-6, CD33, TYROBP, C-Reactive Protein (CRP), IL-1β and 
MSA4A (Jones et al., 2015, Vanltallie, 2017, Dansokho and Heneka, 2017, Karch et al., 
2014 See Dansokho et al. for more). These genes are thought to contribute to the 
neuroinflammation that exists in demented brains, although how much each gene 
contributes, and their mechanisms have not been fully elucidated.  
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When compared with inflammatory genes that are downregulated during exercise, 
there seems to be a compelling overlap between several genes, namely between TNF-α, 
IL-6, IL-1β, & CRP (Sloan et al., 2007, Ryan et al., 2016, Kohut et al., 2006, Lakka et al., 
2005, Flynn et al., 2007, Kasapis and Thompson, 2005, Kang et al., 2013). If aerobic 
exercise can neutralize the inflammatory genes and cytokines that are upregulated in AD 
and arrest or at least lower neuroinflammation, it may be an effective way to ameliorate 
the symptoms and pathologies of the disease. The evidence supporting this hypothesis is 
scant, in part because studies scrutinizing this theory are few and results from these 
studies are inconclusive. Only a very few studies have investigated how aerobic exercise 
affects the inflammatory markers in the CNS and fewer have been done when evaluating 
AD cases.  
Despite this, there have been many studies that explore how exercise exerts an 
anti-inflammatory response throughout the body regarding other diseases like 
cardiovascular disease. Based on these studies there may be exciting parallels to what can 
occur in the CNS and they may still enlighten us on the possible effects of exercise on 
inflammation in the demented brain. 
 
Non-AD Studies: exercise and inflammatory gene expression 
Exercise has been shown time and again to reduce CRP, TNF-alpha, IL-6, IL-1β, 
and other inflammatory markers throughout the body. In 2005, Lakka et al., determined 
through a 20-week exercise program that aerobic exercise lowers levels of CRP in 
sedentary adults with high levels of CRP.  Researchers took parents (age 65 or younger) 
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and their children (age 17 or older) and subjected them to an exercise regimen. The 
results of reduced CRP were consistent across the board. Sloan et al., Flynn et al., 
Kasapis and Thompson, Kohut et al., and Petersen and Pedersen all came to similar 
conclusions.  
Sloan et al. studied young sedentary adults aged 20-45 years old. They broke up 
their subjects into two groups, a moderate-intensity exercise group and a high-intensity 
exercise group. They found that only the high-intensity exercise group led to a decrease 
in TNF-alpha and CRP release. In a review study, Flynn et al. argued that although more 
research is needed, the majority of studies agree that physical activity and physically fit 
people have lower levels of IL-6, TNF-alpha, CRP, and IL-1β.  
In a separate systematic review, Kasapis and Thompson found that strenuous 
exercise produced a short term inflammatory response during an Acute Phase Response 
(APR) to the physical exertion (See Figure 7). They showed that pro-inflammatory 
cytokines (IL-6 and IL-1) increase, while TNF-alpha stays relatively the same. There was 
also an increase of anti-inflammatory markers, namely IL-8, IL-10 and macrophage 
inflammatory proteins 1 (MIP-1).  
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Figure 7. Exercise and Inflammatory Marker Release. Shows effect of strenuous 
exercise on the release of inflammatory markers. (From Kasapis and Thompson 2005) 
 
In contrast, they found that regular physical activity was inversely related to 
inflammatory marker concentration. They suggest that physical activity needs to be 
consistent to produce the anti-inflammatory response, citing a study by Wannamethee et 
al. that showed when active men stopped exercising their CRP levels increased to those 
found in sedentary men who remained inactive, showing that CRP levels, and the anti-
inflammatory response, need constant upkeep. 
Interestingly, Kohut et al. found that not only does aerobic exercise reduce levels 
of IL6, TNF-alpha, IL-18, and CRP, these reductions also correlated with improvement in 
depression, optimism, and a sense of coherence. These psychosocial results may be due 
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to several aspects and results of exercise.  Further research is needed to determine the 
exact mechanisms.  
Petersen and Pedersen suggest that chronic-low grade inflammation occurs as 
people age, with aged people showing increased levels of TNF-alpha, IL-6, and CRP. 
They implicated adipose tissue as the major producer of TNF-alpha, which also increases 
IL-6, IL-1, and CRP. They showed that IL-6 is released from muscles during exercise and 
directly mimics the levels of TNF-alpha and, in contrast to the above studies, suggest that 
IL-6 has important anti-inflammatory effects. It causes these effects by inhibiting TNF-
alpha and IL-1 and through increasing production of IL-1ra and IL-10, both anti-
inflammatory cytokines. Despite these differences, the conclusion is the same, that 
exercise can be used to ameliorate systemic inflammation. 
In a separate study, Kohman et al. investigated the effects that exercise may have 
on microglia activity, finding that the hippocampus, and microglia in the hippocampus, 
are particularly responsive to exercise. They discovered that aerobic exercise can alter the 
activation of microglia in the hippocampus, which in turn, changes the cytokines and 
inflammatory genes used by the microglia.  
These studies show a pronounced anti-inflammatory response of exercise in 
people of all ages. The evidence of exercise directly modifying microglia and the release 
of inflammatory cytokines and markers is compelling. It is also interesting to note that 
several of the studies found regular, long-term exercise being the most beneficial in 
promoting the anti-inflammatory effect when studying other diseases. A potential parallel 
can be drawn when comparing these data with that found in the reduction in AD risk in 
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people who exercise throughout their lives. Perhaps the reduced risk in AD in people that 
exercise is due in part to the lowering of inflammation systemically and in the CNS.  
 
AD Models 
Exercise downregulate pro-inflammatory markers, and also upregulates anti-
inflammatory markers. In a Tg2576 AD mouse model sedentary mice were found to 
overexpress the pro-inflammatory IL-1β and TNF-alpha more so than wild type mice. In 
addition, aerobic exercise lowered expression of IL-1β and TNF-alpha to levels similar 
with that of wild type mice (Stranahan et al., 2012). Ryan et al. focused on the 
inflammation of the hippocampus and the results of exercise in this tissue. They found 
that AD models show decreases in hippocampal IL-1β and TNF-alpha, as well as 
increases in CXCL1 and CXCL12 which are neuroprotective chemokines. They further 
suggest that exercise may have direct effects on microglia activity in the hippocampus.  
 
Role of Microglia in AD Pathology 
Microglia has been shown to have a higher density in the hippocampus than other 
parts of the brain (Kohman et al.). In studying the regulation of unfolded protein response 
(UPR) Kang et al. found that treadmill running in a 3xTg mutant mouse model of AD 
showed a decrease in TNF-alpha and IL-1alpha, possibly through modification of the 
UPR. 
Interestingly, AD models show evidence that exercise extends its anti-
inflammatory affect into the CNS and quite possibly through modification of microglia. 
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These studies show a marked decrease in pro-inflammatory cytokines, especially TNF-
alpha, IL-1, and CRP. It has been shown that activated microglia are responsible for 
releasing TNF-alpha and IL-1 in the CNS (Su et al., 2016 & Balducci & Forloni, 2018). 
In this light, the hypothesis the ant-inflammatory effects from exercise are due to the 
modification of microglia is appealing. Microglia are the resident immune cells of the 
brain and the first line of defense in response to pathogens. They recognize exogenous 
and endogenous CNS insults and are vital to a healthy brain environment, while 
comprising between 10-15% of all CNS cells (Solito and Satre, 2012 & Balducci and 
Forloni, 2018). Once thought to primarily be phagocytic cells, recent discovery has 
shown microglia have a variety of functions including phagocytosis of synaptic 
structures, active remodeling of presynaptic environment, and the release of soluble 
factors in the mature and aging brain. Microglia also act as critical mediators in the 
modulation of neurogenesis (Su et al., 2016). 
Microglia exist in two major states: resting and activated. In the resting state, 
microglia are on a continuous patrol of the neuronal environment. They contribute to 
tissue homeostasis, release neurotrophic factors, and survey the activity of synapses to 
ensure regular processing of new memories (Balducci and Forloni, 2018, Sarius and 
Heneka, 2017, and Chitnis & Weiner, 2017). They express a collection of innate immune 
receptors including Toll-like receptors (TLRs), scavenger receptors, and receptors for 
advanced glycosylation end products. These respond to pathogen-associated molecular 
patterns (PAMPs) or damage-associated molecular patterns (DAMPs).  
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TLRs have been scrutinized in recent years for their role in AD. They are a family 
of pattern recognition receptors expressed on microglia (Balducci & Forloni, 2018). It has 
been shown that several types of TLRs are associated with AD, mainly due to their 
phagocytic and inflammatory response when recognizing and responding to AB 
oligomers and plaques and other misfolded proteins (Dansokho and Heneka, 2017, 
Heneka, 2017). Activation of these TLRs is what leads to the release of proinflammatory 
cytokines like TNF-alpha, IL-6, and IL-1B (Su et al., 2016 & Balducci & Forloni, 2018). 
Disrupting and/or blocking the downstream cascade of TLRs has been shown to improve 
the clearance of AB and shift microglial cells to an anti-inflammatory phenotype (Heneka 
et al., 2015 and Dansokho & Heneka, 2017). 
When encountering pathogens through TLRs, microglia can transform into the 
activated state. In the active state, microglia increase in number, undergo phenotypic 
changes, and changes in secretory mediator and proliferative response (Balducci and 
Forloni, 2018 & Sarius and Heneka, 2017). They express and release a number of 
inflammatory markers including CD36, CD14, CD11c, MHC-11, iNOS, IL-1β, IL-6, 
TNF-alpha, IL-8, macrophage inflammatory protein-1alpha and marks of the M1 
phenotype (Sarius and Heneka, 2017 & Solito and Satre, 2012, Dansokho & Heneka, 
2017). This induces an inflammatory response which resolves the insult. It is also this 
inflammatory response, when it becomes chronic and over exaggerated, that exacerbates 
the symptoms of AD (See Figure 8). 
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Figure 8. Activated Microglia. Shows the possible negative results of activated 
microglia. (From Balducci and Forloni, 2018) 
 
Neuroinflammation acts as a double-edged sword when it comes to AD. In the 
early stages of AD and during an acute inflammatory response, neuroinflammation may 
play a protective function in the development of AD. It can help defend the brain and 
CNS and aid in the removal of cell debris and toxic factors, with one of its primary 
beneficial function being the removal of amyloid through microglia (Balducci and 
Forloni, 2018).   
Yet, chronic inflammation has been implicated as a driving force behind AD and 
studies have shown inflammation playing a key role in AD through neuronal damage, 
increased Aβ generation, increased phosphorylation of tau, and cognitive impairment 
(Solito and Satre, 2012 & Sarius and Heneka, 2017). Inflammation and Aβ generation 
may even create a positive feedback mechanism, where inflammation increases Aβ 
generation through increasing the transcription of BACE1 and Aβ generation increasing 
the inflammatory response (Solito and Satre, 2012, Heneka et al., 2015). It has also been 
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shown that stimulation of the immune system by AB deposits and proinflammatory 
cytokines impairs the ability of microglia to clear AB. Additionally, the activation of the 
immune system may reduce microglial capacity to produce neurotrophic factors (Heneka 
et al. 2015). 
There are many theories into why and how microglia maintain their chronic 
activation. One intriguing hypothesis is that the microglia develop a gene-expression 
pattern that is unlike the gene-expression shown by the microglia that resided in the brain 
before being activated. Over time, the new microglia could maintain this expression 
pattern and sustain a chronic neuroinflammation in AD (Heneka et al., 2015). 
Another theory is that when microglia become activated in AD, they surround the 
neurons with AB build up until they can remove the insult. It is when they cannot remove 
the buildup that they slip into chronic inflammation. The microglia stay surrounded 
around the neuron, continuously attacking it and releasing pro-inflammatory cytokines, 
essentially killing the neuron and promoting the neurodegenerative process (Balducci and 
Forloni, 2018).  
Despite not knowing the exact process of maintaining the chronic inflammatory 
state of microglia, the evidence points to microglia playing an integral part in AD. With 
the additional evidence that exercise possibly alters microglial activation, it stands to 
reason that exercise may attribute it’s lowering of AD risk to microglial modification. 
Certainly, more studies need to be done to assess this hypothesis, but the current evidence 
looks promising. Microglia may very well be the key to preventing and/or reversing AD. 
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NSAIDs 
It is reasonable to believe that if inflammation is a driving force behind AD, then 
taking Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may alleviate symptoms 
(Heneka et al., 2015). Although compelling, the research and evidence is awash with 
disagreement. A 2002 study by Lindsay et al. followed 4,088 people over a 5-year period 
and found that the use of NSAIDs reduced the risk of Alzheimer’s disease by 35%. 
Although they did not discuss the mechanism for why, one can assume these results are 
due in part from the anti-inflammatory effect of the drugs. In a separate study in 2017 by 
McGeer et al. they hypothesized that NSAIDs may be effective as a preventative 
treatment, only if they are started well before the onset of clinical symptoms. Several 
other studies have shown that NSAIDs do not offer any protective function in the 
development of AD (Miguel-Alvarez et al., 2015 & Wang et al., 2015). Further studies 
and experiments are needed to determine if altering the dosage, time of dosage in a 
person’s lifetime, and type of NSAID would have differing results.  
Even if treatment with NSAIDs became a viable option, taking them over a 
prolonged time period would still present with adverse health risks. There are several 
common side-effects of these drugs, including heart attack, stroke, gastrointestinal pain, 
stomach ulcers, headaches, dizziness, liver and kidney problems, and high blood 
pressure. 
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DISCUSSIONS AND CONCLUSIONS 
 
Potential Impact on AD Prevention & Treatment 
 As discussed at the beginning of this review, the societal impact of AD is 
enormous. Millions of people are suffering with the disease throughout the US and the 
world, with that number only projected to increase dramatically in the coming years. 
Along with this health care crisis, billions and soon to be trillions of dollars are being and 
will be spent to provide adequate care for people diagnosed with AD. The disease does 
not just destroy the lives of the people who have it, it hinders and dismantles the lives of 
the loved ones who are drained emotionally, physically and financially as caregivers. 
With an estimated 33% of all AD cases being caused by modifiable risk factors, 
the possible prevention and treatment of AD with aerobic exercise could be massive. 
Additionally, if inflammation is the driving force behind AD, the administration of 
NSAIDs or some other anti-inflammatory drug could be a relatively safe, cost efficient 
way to treat disease. Drug side effects, primarily gastrointestinal issues, liver and kidney 
problems, and high blood pressure, would have to be taken into consideration. If 
researchers can determine the adequate dose of exercise needed and the optimal time of 
administration to stave off disease, it could be an almost risk free and cost-free 
prevention that could potentially save millions of lives, trillions of dollars, and the 
emotional well-being of millions more who live with and care for relatives and friends 
who struggle with disease.  
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Future Directions 
         The research is almost unanimous in its support of physical activity playing a 
protective and preventive role in the development of AD. The evidence is consistent 
across all types of studies and all subjects including human and animal. Despite this, 
there are still several vital questions that need to be answered for scientists to create a 
viable treatment centering around exercise.   
First, when is the best time in a person’s life to engage in physical exercise so to 
provide the greatest amount of protection against AD? Is it in middle to late age when 
scientists believe AB plaques are beginning to form or some other time? Most researchers 
agree that treatments for AD have not been effective due to the administration time being 
too late in disease development. Determining the opportune age for treatment may be the 
key to unlocking the greatest cognitive benefits seen with exercise in AD patients. 
Second, what is the optimal dosage and best type of exercise to create the positive 
effects. Research points to aerobic exercise offering more benefits than weight or strength 
training alone, but this has not been confirmed. Additionally, the dosage has not been set. 
Scientists do not know how often, how long, or at what intensity exercise should be for 
the greatest protective results. 
Third, what is the mechanism behind the protective cognitive function of 
exercise? Several potential mechanisms have been elucidated including those involving 
HDACs, BDNF, BACE1, and alterations of microglia. Understanding which mechanism 
 39 
will allow scientists to not only manipulate the pathway through exercise, but also 
through pharmaceutical efforts. 
Future studies should include more robust and meticulous RCTs with the above-
mentioned questions at the center of the study. Previous RCTs have been criticized for 
their lack of attention to detail and relatively small sample size, which confounded their 
results. These studies often lacked homogeneity in their subjects with dementia, with 
patients in all stages of AD and other types of dementia, contributing to uncertain results. 
Unfortunately, short-term RCTs may not be powerful enough to conclusively answer the 
question of what age in a person’s life is physical exercise most beneficial against AD. A 
longitudinal study would need to be administered to track progression over lengthy 
periods of time, potentially decades. Although long-term follow up and tracking is 
needed to fully consider the protective functions of exercise against AD, it is not entirely 
practical when a solution for AD is needed now. 
Considering the time sensitive nature of finding a treatment, this review proposes 
that future RCTs focus on the molecular mechanisms of neuroinflammation in AD by 
measuring levels of pro- and anti-inflammatory cytokines in the blood and microglial 
activation in the brain at baseline and after aerobic exercise in individuals with dementia 
and those without symptoms. Microglial activation can be measured using a radiotracer 
and positron emission tomography (PET) in living human brains (Sandiego et al., 2015). 
It would also be important to have meticulously detailed exercise programs and cognitive 
tests. A recommendation on the best cognitive tests to administer is not given here, but 
these tests should be powerful enough to detect changes in executive function, global 
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cognition, and verbal frequency. Additionally, AD patients should be screened more 
heavily prior to participation in the RCTs and grouped by severity of disease. If 
inflammation is indeed a key player in the cognitive decline shown in AD patients, the 
mechanisms of how exercise manipulates neuroinflammation should be elucidated. 
 
CONCLUSION 
         With no cure, the increasing human lifespan, and the accompanying projected 
increase in AD cases, the world is in desperate need of a powerful Alzheimer’s disease 
deterrent. Recent evidence suggests that physical exercise has the potential to be that 
needed protector. Whether those protective effects occur from exercise’s anti-
inflammatory abilities and alterations of microglia activity or its ability to change levels 
of BDNF and BACE1, exercise has shown real promise in being a cost-effective, almost 
risk-free avenue to lowering a person’s risk of developing AD and in alleviating the 
symptoms of millions who have it.  
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